Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2008-01-15
2008-01-15
Crouch, Deborah (Department: 1632)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C424S450000
Reexamination Certificate
active
07319094
ABSTRACT:
The invention features a non-transgenic model of Alzheimer's Disease, method for inducing prolonged in vivo gene expression in a mammal, and methods of inhibiting Alzheimer's Disease-associated neuronal cell death.
REFERENCES:
patent: 5744335 (1998-04-01), Wolff et al.
patent: 5800390 (1998-09-01), Hayakawa et al.
patent: 5863898 (1999-01-01), Goli et al.
patent: 5948634 (1999-09-01), De la Monte et al.
patent: 6071075 (2000-06-01), Tomita et al.
patent: 6180784 (2001-01-01), Wolff et al.
patent: WO 94/23756 (1994-10-01), None
patent: WO 96/15272 (1996-05-01), None
patent: WO 98/38204 (1998-09-01), None
patent: WO 98/39967 (1998-09-01), None
Zou et al. Liposomal-Mediated NGF Gene Transfection Following Neuronal Injury: Potential Therapeutic Applications. Gene Therapy. 1999, vol. 6, pp. 994-1005.
Budker et al., “Protein/amphipathic polyamine complexes enable highly efficient transfection with minimal toxicity”,BioTechniques, 23(1):139-147 (1997).
De la Monte et al., “Neurodegeneration changes in primary central nervous system neurons transfected with the Alzheimer-associated neuronal thread protein gene”,CMLS Cell. Mol. Life Sci., 58(5/6):844-849 (2001).
De la Monte et al., “Alzheimer-associated neuronal thread protein-induced apoptosis and impaired mitochondrial function in human central nervous system-derived neuronal cells”,J. Neuropathol. Exper. Neurol., 60(2):195-207 (2001).
Fritz et al., “Gene transfer into mammalian cells using histone-condensed plasmid DNA”,Hum. Gene Ther., 7:1395-1404 (1996).
Hagstrom et al., “Complexes of non-cationic liposomes and histone H1 mediate efficient transfection of DNA without encapsulation”,Biochimica et Biophysica Acta, 1284:47-55 (1996).
Schwartz et al., “Synthetic DNA-compacting peptides derived from human sequence enhance cationic lipid-mediated gene transfer in vitro and in vivo”,Gene Ther., 6:282-292 (1999).
Melani et al., “Inhibition of Proliferation by c-mybAntisense Oligodeoxynucleotides in Colon Adenocarcinoma Cell Lines That Express c-myb,” Cancer Res. 51:2897-2901, 1991.
Quon et al, Formation of β-Amyloid Protein Deposits in Brains of Transgenic Mice. Nature, Jul. 18, 1991, vol. 352, pp. 239-241.
Sullivan et al., “Development of Ribozymes for Gene Therapy,” 1994, J. Invest. Derm. 103:85S-89S.
Kahle , et al., “Combined Assessment of Tau and Neuronal Thread Protein in Alzheimer's Disease CSF”,Neurology, 54:1498-1504 (2000).
Kõiv, et al., “Evidence for Ternary Complex Formation by Histone HI, DNA, and Liposomes”,Biochemistry, 34:8018-8027 (1995).
Zelphati, et al., “Mechanism of Oligonucleotide Release from Cationic Liposomes”,Proc. Natl. Acad. Sci. USA, 93:11493-11498 (1996).
Zhao, et al., “Alternative Pulmonary Defense in Transgenic Mice Deficient in NOS Isozymes by Gene-Knockout Technique”, Abstract,FASEB Journal, 3(5):A1015 (1999).
Nishimura et al. (1998) Degeneration in vivo of Rat Hippocampal Neurons by Wild-Type Alzheimer Amyloid Precursor Protein Overexpressed by Adenovirus-Mediated Gene Transfer. Journal of Neuroscience. vol. 18, No. 7, pp. 2387-2398.
Games et al. (1992) Lack of Alzheimer Pathology After Beta-Amyloid Protein Injections in Rat Brian. Neurobiology of Aging. vol. 13, pp. 569-576.
Podlinksy et al. (1992) Synthetic Amyloid Beta-Protein Fails to Produce Specific Neurotoxicity in Monkey Cerebral Cortex. Neurobiology of Aging. vol. 13, pp. 561-567.
Czubayko et al., “Ribozyme-Elucidates a Direct Role of Pleiotrophin in Tumor Growth,” 1994, J. Biol. Chem. 269:21358-21363.
de la Monte et al., “Microtiter Immunocytochemical ELISA Assay”, 1999, Biotechniques 26:1073-1076.
de la Monte et al., “Characterization of the AD7C-NTP cDNA Expression in Alzheimer's Disease and Measurement of a 41-kD Protein in Cerebrospinal Fluid,” 1997, J. Clin. Invest. 100(12):30393-3104.
de la Monte et al., “Aberrant expression of nitric oxide synthase III in Alzheimer's disease: relevance to cerebral vasculopathy and neurodegeneration,” Neurobiol. Aging, Mar.-Apr. 2000; 21(2): 309-319.
Kobayashi et al., “Reversal of Drug Sensitivity in Multi-Resistant Tumor Cells by anMDRI (PGYI) Ribozyme,” 1994, Cancer Res. 54:1271-1275.
Mahieu et al, “Construction of a Ribozyme Directed Against Human Interleukin-6 mRNA: Evaluation of Its Catalytic Activity In Vitro and In Vivo,” 1994, Blood 84:3758-65.
GENBANK Accession No. NM—014486, Feb. 21, 2005.
GENBANK Accession No. AF010144, Nov. 2, 2001.
De La Monte Suzanne M.
Wands Jack R.
Beattie Ingrid A.
Crouch Deborah
Mintz Levin Cohn Ferris Glovsky and Popeo P.C.
Rhode Island Hospital
LandOfFree
Increased and sustained in vivo gene expression using a... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Increased and sustained in vivo gene expression using a..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Increased and sustained in vivo gene expression using a... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2777764